<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072761</url>
  </required_header>
  <id_info>
    <org_study_id>R01NS42804</org_study_id>
    <secondary_id>5U01NS042804-07</secondary_id>
    <nct_id>NCT00072761</nct_id>
  </id_info>
  <brief_title>Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial</brief_title>
  <acronym>SIT</acronym>
  <official_title>Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine the effectiveness of blood transfusion therapy for
      prevention of silent cerebral infarct (stroke) in children with sickle cell anemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Silent cerebral infarct (stroke) is the most common cause of severe cognitive impairments and
      related neurological functions in children with sickle cell anemia. Currently there exists no
      systemic strategy to identify or treat children with silent strokes.

      The primary aim of this trial is to determine the effectiveness of blood transfusion therapy
      for the prevention of silent strokes in children with sickle cell anemia. This trial will
      also determine if blood transfusion therapy will prevent further cerebral injury and if the
      measured benefits of the therapy outweigh the risks associated with it.

      Participants in this multi-center trial will be randomly assigned to one of 2 groups-the
      blood transfusion group or the observation group. Those in the blood transfusion group will
      receive at least monthly blood transfusion therapy. All participants will have history and
      physical examinations every 3 months, and magnetic resonance imaging (MRI) at the beginning
      of their entry into the study and at study exit.

      Advances in the understanding and treatment of silent strokes will likely lead to a decrease
      in the burden associated with cerebral injury in children with sickle cell anemia and change
      the standard care for these children.

      Statistical Analyses: The original statistical analysis plan suggested a simple difference in
      proportions between the proportion of individuals with an endpoint in the transfusion group
      and the proportion of individuals with an endpoint in the usual care group using a
      traditional chi squared test. The data should be analyzed according to an intent to treat
      principal. Because of various logistical concerns in SIT, some individuals were not imaged
      within the 36-month window (30-42 months). We propose using all available information by
      changing the primary analysis from a dichotomous (yes/no) endpoint to a traditional
      epidemiological endpoint of an incidence rate in the group randomized to transfusion to the
      incidence rate in the group randomized to usual care. We will compute the incidence ratio:

      (a/ta)/(b/tb)

      Where &quot;a&quot; is the number of endpoints in the transfusion group, &quot;ta&quot; is the sum of the
      individual times at risk of the individuals randomized to the transfusion group, &quot;b&quot; is the
      number of endpoints in the observation group and &quot;tb&quot; is the sum of the individual times at
      risk of the individuals randomized to the observation group.

      Since the standard statistical test for it being different than 1.0 involves the assumption
      of a Poisson distribution, we will compute an &quot;exact&quot; 95% confidence interval using a
      bootstrap with a large number of replications.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of an Infarct, Defined as a Stroke or a New or Enlarged Silent Cerebral Infarct</measure>
    <time_frame>From study entry to study exit</time_frame>
    <description>The primary end point was the recurrence of infarct or hemorrhage as determined by neuroimaging, clinical evidence of permanent neurologic injury, or both. A new infarct had to meet the criteria for a silent cerebral infarction; an enlarged silent cerebral infarct was defined as a previously identified silent cerebral infarct that increased by at least 3 mm along any linear dimension in any plane on MRI.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">196</enrollment>
  <condition>Sickle Cell Anemia</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Transfusion Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants allocated to the transfusion arm will receive blood transfusion therapy every 4-6 weeks for 36 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants allocated to the observation arm will be treated according to standard care and will receive a quarterly physical examination by a study hematologist for 36 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transfusion therapy</intervention_name>
    <description>Those in the blood transfusion group will receive at least monthly blood transfusion therapy.</description>
    <arm_group_label>Transfusion Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION:

          -  Patient must have sickle cell anemia (hemoglobin SS) or sickle beta thalassemia
             (hemoglobin SB) as confirmed at the local institution.

          -  Participating institutions must submit documentation of the diagnostic hemoglobin
             analysis to the Statistical and Clinical Coordinating Centers to confirm the diagnosis
             of sickle cell anemia prior to randomization.

          -  Patient must be 5 through 14 years of age.

          -  Patient must have a cerebral infarct documented by MRI scan as read by the
             neuroradiology panel.

          -  Informed consent with assent in accordance with the institutional policies
             (institutional Institutional Review Board approval) and Federal guidelines (approved
             by the United States Department of Health and Human Services) must be signed by the
             patient's legally authorized guardian acknowledging written consent to join the study.
             When suitable, patients will be requested to give their assent to join the study.

        EXCLUSION:

          -  Patient with a history of a focal neurologic event lasting more than 24 hours with
             medical documentation or a history of prior overt stroke.

          -  Patients with a transcranial doppler (TCD) study with a time-averaged mean velocity
             greater than 200 cm/sec verified by the study radiologist.

          -  Patients with other neurological problems, such as neurofibromatosis, lead poisoning,
             or tuberous sclerosis.

          -  Patients with HIV infection.

          -  Pregnancy.

          -  Patients who received treatment with anti-sickling drugs or hydroxyurea within 3
             months or anticipate receiving anti-sickling drugs or hydroxyurea during the course of
             the study.

          -  Abnormal kidney function (creatinine &gt; 2x upper limit of normal).

          -  Patients on chronic blood transfusion therapy for other reasons.

          -  Patients judged not likely to be compliant by his/her hematologist and local nurse
             coordinator based on previous compliance in clinic appointments and following advice.
             Specifically, families that have missed at least two appointments without notification
             within 12 months prior to the trial or parents of potential patients that have been
             reported for medical or education neglect are not eligible for this trial.

          -  Patients unable to receive blood transfusion because of alloimmunization.

          -  Patients with permanent or semi-permanent metallic (braces on teeth) structures
             attached to their body. Such patients cannot obtain a MRI of the head to assess the
             presence of silent cerebral infarcts.

          -  Siblings randomized in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R. DeBaun, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pediatrics.mc.vanderbilt.edu/sit</url>
    <description>official study website</description>
  </link>
  <reference>
    <citation>Buchanan GR, DeBaun MR, Quinn CT, Steinberg MH. Sickle cell disease. Hematology Am Soc Hematol Educ Program. 2004:35-47. Review.</citation>
    <PMID>15561675</PMID>
  </reference>
  <reference>
    <citation>Vendt BA, McKinstry RC, Ball WS, Kraut MA, Prior FW, Barton B, Casella JF, DeBaun MR. Silent Cerebral Infarct Transfusion (SIT) trial imaging core: application of novel imaging information technology for rapid and central review of MRI of the brain. J Digit Imaging. 2009 Jun;22(3):326-43. doi: 10.1007/s10278-008-9114-3. Epub 2008 Apr 9.</citation>
    <PMID>18398653</PMID>
  </reference>
  <reference>
    <citation>Casella JF, King AA, Barton B, White DA, Noetzel MJ, Ichord RN, Terrill C, Hirtz D, McKinstry RC, Strouse JJ, Howard TH, Coates TD, Minniti CP, Campbell AD, Vendt BA, Lehmann H, Debaun MR. Design of the silent cerebral infarct transfusion (SIT) trial. Pediatr Hematol Oncol. 2010 Mar;27(2):69-89. doi: 10.3109/08880010903360367.</citation>
    <PMID>20201689</PMID>
  </reference>
  <reference>
    <citation>Jordan LC, McKinstry RC 3rd, Kraut MA, Ball WS, Vendt BA, Casella JF, DeBaun MR, Strouse JJ; Silent Infarct Transfusion Trial Investigators. Incidental findings on brain magnetic resonance imaging of children with sickle cell disease. Pediatrics. 2010 Jul;126(1):53-61. doi: 10.1542/peds.2009-2800. Epub 2010 Jun 14.</citation>
    <PMID>20547639</PMID>
  </reference>
  <reference>
    <citation>Bhatnagar P, Purvis S, Barron-Casella E, DeBaun MR, Casella JF, Arking DE, Keefer JR. Genome-wide association study identifies genetic variants influencing F-cell levels in sickle-cell patients. J Hum Genet. 2011 Apr;56(4):316-23. doi: 10.1038/jhg.2011.12. Epub 2011 Feb 17.</citation>
    <PMID>21326311</PMID>
  </reference>
  <reference>
    <citation>Jordan LC, Casella JF, DeBaun MR. Prospects for primary stroke prevention in children with sickle cell anaemia. Br J Haematol. 2012 Apr;157(1):14-25. doi: 10.1111/j.1365-2141.2011.09005.x. Epub 2012 Jan 9. Review.</citation>
    <PMID>22224940</PMID>
  </reference>
  <reference>
    <citation>DeBaun MR, Sarnaik SA, Rodeghier MJ, Minniti CP, Howard TH, Iyer RV, Inusa B, Telfer PT, Kirby-Allen M, Quinn CT, Bernaudin F, Airewele G, Woods GM, Panepinto JA, Fuh B, Kwiatkowski JK, King AA, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Sabio H, Gonzalez CE, Saccente SL, Kalinyak KA, Strouse JJ, Fixler JM, Gordon MO, Miller JP, Noetzel MJ, Ichord RN, Casella JF. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood. 2012 Apr 19;119(16):3684-90. doi: 10.1182/blood-2011-05-349621. Epub 2011 Nov 17.</citation>
    <PMID>22096242</PMID>
  </reference>
  <reference>
    <citation>Thangarajh M, Yang G, Fuchs D, Ponisio MR, McKinstry RC, Jaju A, Noetzel MJ, Casella JF, Barron-Casella E, Hooper WC, Boulet SL, Bean CJ, Pyle ME, Payne AB, Driggers J, Trau HA, Vendt BA, Rodeghier M, DeBaun MR. Magnetic resonance angiography-defined intracranial vasculopathy is associated with silent cerebral infarcts and glucose-6-phosphate dehydrogenase mutation in children with sickle cell anaemia. Br J Haematol. 2012 Nov;159(3):352-9. doi: 10.1111/bjh.12034. Epub 2012 Sep 7.</citation>
    <PMID>22958163</PMID>
  </reference>
  <reference>
    <citation>Quinn CT, McKinstry RC, Dowling MM, Ball WS, Kraut MA, Casella JF, Dlamini N, Ichord RN, Jordan LC, Kirkham FJ, Noetzel MJ, Roach ES, Strouse JJ, Kwiatkowski JL, Hirtz D, DeBaun MR. Acute silent cerebral ischemic events in children with sickle cell anemia. JAMA Neurol. 2013 Jan;70(1):58-65. doi: 10.1001/jamaneurol.2013.576.</citation>
    <PMID>23108767</PMID>
  </reference>
  <reference>
    <citation>Bean CJ, Boulet SL, Ellingsen D, Pyle ME, Barron-Casella EA, Casella JF, Payne AB, Driggers J, Trau HA, Yang G, Jones K, Ofori-Acquah SF, Hooper WC, DeBaun MR. Heme oxygenase-1 gene promoter polymorphism is associated with reduced incidence of acute chest syndrome among children with sickle cell disease. Blood. 2012 Nov 1;120(18):3822-8. doi: 10.1182/blood-2011-06-361642. Epub 2012 Sep 10.</citation>
    <PMID>22966170</PMID>
  </reference>
  <reference>
    <citation>Milton JN, Sebastiani P, Solovieff N, Hartley SW, Bhatnagar P, Arking DE, Dworkis DA, Casella JF, Barron-Casella E, Bean CJ, Hooper WC, DeBaun MR, Garrett ME, Soldano K, Telen MJ, Ashley-Koch A, Gladwin MT, Baldwin CT, Steinberg MH, Klings ES. A genome-wide association study of total bilirubin and cholelithiasis risk in sickle cell anemia. PLoS One. 2012;7(4):e34741. doi: 10.1371/journal.pone.0034741. Epub 2012 Apr 27.</citation>
    <PMID>22558097</PMID>
  </reference>
  <reference>
    <citation>DeBaun MR, Armstrong FD, McKinstry RC, Ware RE, Vichinsky E, Kirkham FJ. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood. 2012 May 17;119(20):4587-96. doi: 10.1182/blood-2011-02-272682. Epub 2012 Feb 21. Review.</citation>
    <PMID>22354000</PMID>
  </reference>
  <reference>
    <citation>Glassberg JA, Wang J, Cohen R, Richardson LD, DeBaun MR. Risk factors for increased ED utilization in a multinational cohort of children with sickle cell disease. Acad Emerg Med. 2012 Jun;19(6):664-72. doi: 10.1111/j.1553-2712.2012.01364.x.</citation>
    <PMID>22687181</PMID>
  </reference>
  <reference>
    <citation>An P, Barron-Casella EA, Strunk RC, Hamilton RG, Casella JF, DeBaun MR. Elevation of IgE in children with sickle cell disease is associated with doctor diagnosis of asthma and increased morbidity. J Allergy Clin Immunol. 2011 Jun;127(6):1440-6. doi: 10.1016/j.jaci.2010.12.1114. Epub 2011 Mar 9.</citation>
    <PMID>21388662</PMID>
  </reference>
  <results_reference>
    <citation>DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, Telfer PT, Kirby-Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014 Aug 21;371(8):699-710. doi: 10.1056/NEJMoa1401731.</citation>
    <PMID>25140956</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2003</study_first_submitted>
  <study_first_submitted_qc>November 12, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2003</study_first_posted>
  <results_first_submitted>May 4, 2015</results_first_submitted>
  <results_first_submitted_qc>January 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 8, 2016</results_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Michael DeBaun</investigator_full_name>
    <investigator_title>Professor or Pediatrics and Medicine, JC Peterson Endowed Chair, Vice Chair of Clinical Research</investigator_title>
  </responsible_party>
  <keyword>silent cerebral infarct</keyword>
  <keyword>silent stroke</keyword>
  <keyword>sickle cell anemia</keyword>
  <keyword>stroke</keyword>
  <keyword>transfusion therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began in December, 2004 and ended May, 2010. Among the 1074 children screened with a MRI of the brain, 1.9% (20 of 1074) had strokes and 35.2% (379 of 1074) had infarct-like lesions. 196 participants completed all pre-randomization procedures and were successfully randomly allocated.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Transfusion Group</title>
          <description>The transfusion group received blood transfusion therapy every 4-6 weeks for 36 months.</description>
        </group>
        <group group_id="P2">
          <title>Observation Group</title>
          <description>The observation group received standard care therapy and quarterly physical examination by a study hematologist for 36 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Transfusion Group</title>
          <description>The transfusion Group received blood transfusion therapy every 4-6 weeks for 36 months.</description>
        </group>
        <group group_id="B2">
          <title>Observation Group</title>
          <description>The observation group received standard care therapy and quarterly physical examination by a study hematologist for 36 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="99"/>
            <count group_id="B2" value="97"/>
            <count group_id="B3" value="196"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" lower_limit="5" upper_limit="15"/>
                    <measurement group_id="B2" value="10" lower_limit="5" upper_limit="15"/>
                    <measurement group_id="B3" value="10" lower_limit="5" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recurrence of an Infarct, Defined as a Stroke or a New or Enlarged Silent Cerebral Infarct</title>
        <description>The primary end point was the recurrence of infarct or hemorrhage as determined by neuroimaging, clinical evidence of permanent neurologic injury, or both. A new infarct had to meet the criteria for a silent cerebral infarction; an enlarged silent cerebral infarct was defined as a previously identified silent cerebral infarct that increased by at least 3 mm along any linear dimension in any plane on MRI.</description>
        <time_frame>From study entry to study exit</time_frame>
        <population>Randomization assignments were provided by the statistical data coordinating center with the use of a permuted block design, with stratification according to site, age, and sex. Participants were assigned in a 1:1 ratio to the observation or transfusion group and were followed until study exit or study endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Group</title>
            <description>The transfusion Group received blood transfusion therapy every 4-6 weeks for 36 months.</description>
          </group>
          <group group_id="O2">
            <title>Observation Group</title>
            <description>The observation group received standard care therapy and quarterly physical examination by a study hematologist for 36 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence of an Infarct, Defined as a Stroke or a New or Enlarged Silent Cerebral Infarct</title>
          <description>The primary end point was the recurrence of infarct or hemorrhage as determined by neuroimaging, clinical evidence of permanent neurologic injury, or both. A new infarct had to meet the criteria for a silent cerebral infarction; an enlarged silent cerebral infarct was defined as a previously identified silent cerebral infarct that increased by at least 3 mm along any linear dimension in any plane on MRI.</description>
          <population>Randomization assignments were provided by the statistical data coordinating center with the use of a permuted block design, with stratification according to site, age, and sex. Participants were assigned in a 1:1 ratio to the observation or transfusion group and were followed until study exit or study endpoint.</population>
          <units>infarct recurrence per 100 person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Transfusion Group</title>
          <description>The transfusion Group received blood transfusion therapy every 4-6 weeks for 36 months.</description>
        </group>
        <group group_id="E2">
          <title>Observation Group</title>
          <description>The observation Group received standard care therapy and quarterly physical examination by a study hematologist for 36 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Silent Cerebral Infarct</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vaso-Occlusive Pain</sub_title>
                <counts group_id="E1" events="126" subjects_affected="32" subjects_at_risk="99"/>
                <counts group_id="E2" events="295" subjects_affected="56" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Priapism</sub_title>
                <description>This event was documented in male participants only.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Symptomatic avascular necrosis of the hip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="76" subjects_affected="24" subjects_at_risk="99"/>
                <counts group_id="E2" events="93" subjects_affected="30" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Blood-transfusion reaction</sub_title>
                <counts group_id="E1" events="24" subjects_affected="15" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ferritin &gt; 1500 ng/ml</sub_title>
                <counts group_id="E1" events="1479" subjects_affected="76" subjects_at_risk="90"/>
                <counts group_id="E2" events="33" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Chest Syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E2" events="41" subjects_affected="24" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The SIT Trial results are not directly applicable to all children with SCA. Those who were on hydroxyurea therapy for severe disease, had abnormally elevated TCDs, were receiving blood transfusion for stroke prevention or had epilepsy were excluded.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael R. DeBaun, MD, MPH</name_or_title>
      <organization>Vanderbilt University School of Medicine</organization>
      <phone>615-875-3040 ext 5-3040</phone>
      <email>m.debaun@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

